JP4608495B2 - 第Ｘａ因子阻害剤としてのトリアゾール誘導体 - Google Patents

第Ｘａ因子阻害剤としてのトリアゾール誘導体 Download PDF

Info

Publication number
JP4608495B2
JP4608495B2 JP2006529741A JP2006529741A JP4608495B2 JP 4608495 B2 JP4608495 B2 JP 4608495B2 JP 2006529741 A JP2006529741 A JP 2006529741A JP 2006529741 A JP2006529741 A JP 2006529741A JP 4608495 B2 JP4608495 B2 JP 4608495B2
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
unsubstituted
mono
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006529741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528941A (ja
JP2006528941A5 (https=
Inventor
マルク・ナザレ
フォルカー・ラウクス
アルミン・バウアー
ミヒャエル・ヴァーグナー
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006528941A publication Critical patent/JP2006528941A/ja
Publication of JP2006528941A5 publication Critical patent/JP2006528941A5/ja
Application granted granted Critical
Publication of JP4608495B2 publication Critical patent/JP4608495B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006529741A 2003-05-19 2004-05-05 第Ｘａ因子阻害剤としてのトリアゾール誘導体 Expired - Fee Related JP4608495B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors
PCT/EP2004/004752 WO2004101555A1 (en) 2003-05-19 2004-05-05 TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (3)

Publication Number Publication Date
JP2006528941A JP2006528941A (ja) 2006-12-28
JP2006528941A5 JP2006528941A5 (https=) 2007-06-21
JP4608495B2 true JP4608495B2 (ja) 2011-01-12

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529741A Expired - Fee Related JP4608495B2 (ja) 2003-05-19 2004-05-05 第Ｘａ因子阻害剤としてのトリアゾール誘導体

Country Status (12)

Country Link
EP (2) EP1479679A1 (https=)
JP (1) JP4608495B2 (https=)
AT (1) ATE394396T1 (https=)
AU (1) AU2004238498B2 (https=)
BR (1) BRPI0410763A (https=)
CA (1) CA2526082C (https=)
DE (1) DE602004013577D1 (https=)
IL (1) IL171843A (https=)
MX (1) MXPA05012058A (https=)
PE (1) PE20050154A1 (https=)
TW (1) TW200503694A (https=)
WO (1) WO2004101555A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
RS54303B1 (sr) * 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-člani heterociklični amidi i srodna jedinjenja
WO2009038157A1 (ja) 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. ２，３－ジヒドロ－イミノイソインドール誘導体
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) * 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
IL136637A0 (en) * 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
DE602004013577D1 (de) 2008-06-19
IL171843A (en) 2010-12-30
MXPA05012058A (es) 2006-06-23
JP2006528941A (ja) 2006-12-28
WO2004101555A1 (en) 2004-11-25
EP1628971B1 (en) 2008-05-07
BRPI0410763A (pt) 2006-08-01
ATE394396T1 (de) 2008-05-15
CA2526082C (en) 2012-07-24
EP1479679A1 (en) 2004-11-24
AU2004238498A1 (en) 2004-11-25
AU2004238498B2 (en) 2010-07-22
CA2526082A1 (en) 2004-11-25
PE20050154A1 (es) 2005-04-29
TW200503694A (en) 2005-02-01
EP1628971A1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
JP4585448B2 (ja) 第Ｘａ因子阻害剤としてのピラゾール−誘導体
EP1628972B1 (en) INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US7910606B2 (en) Pyrazole-derivatives as factor Xa inhibitors
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
US7223780B2 (en) Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
JP4658940B2 (ja) 第Ｘａ因子阻害剤としてのベンゾイミダゾール誘導体
JP4733642B2 (ja) 第Ｘａ因子阻害剤としてのアザインドール−誘導体
EP1479678A1 (en) Pyrazole-derivatives as factor xa inhibitors
EP1479674A1 (en) Imidiazole-derivatives as factor xa inhibitors
HK1089174B (en) Benzimidazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100914

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101008

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees